midazolam has been researched along with Hepatocellular Carcinoma in 4 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, the impact of microRNAs (miRNAs) has been identified in hepatocellular carcinoma (HCC), this study was designed to assess the effects of miR-124-3p and midazolam (MDZ) in HCC with the involvement of PIM-1." | 7.96 | Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1. ( Du, X; Qi, Y; Yao, X, 2020) |
| "Recently, the impact of microRNAs (miRNAs) has been identified in hepatocellular carcinoma (HCC), this study was designed to assess the effects of miR-124-3p and midazolam (MDZ) in HCC with the involvement of PIM-1." | 3.96 | Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1. ( Du, X; Qi, Y; Yao, X, 2020) |
| " Based on clearance of CYP isoform-specific substrates at the microsomal level (CLM), microsomal protein per gram of liver (MPPGL), liver weight, hepatic blood flow, hepatic clearance values (CLH) for 10 CYPs in HCC patients (n=102) were extrapolated using a predictive bottom-up pharmacokinetic model." | 1.43 | Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach. ( Fang, Y; Gao, J; Gao, N; He, XP; Jia, LJ; Jin, H; Qiao, HL; Tian, X; Wen, Q; Zhang, YF; Zhou, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D | 1 |
| Soh, CK | 1 |
| Goh, WH | 1 |
| Wang, H | 1 |
| Qi, Y | 1 |
| Yao, X | 1 |
| Du, X | 1 |
| Gao, J | 1 |
| Zhou, J | 1 |
| He, XP | 1 |
| Zhang, YF | 1 |
| Gao, N | 1 |
| Tian, X | 1 |
| Fang, Y | 1 |
| Wen, Q | 1 |
| Jia, LJ | 1 |
| Jin, H | 1 |
| Qiao, HL | 1 |
| Vrzal, R | 1 |
| Kubesova, K | 1 |
| Pavek, P | 1 |
| Dvorak, Z | 1 |
4 other studies available for midazolam and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts | 2018 |
Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell M | 2020 |
Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
Topics: Algorithms; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; GABA Modulators; Humans; Isoe | 2016 |
Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.
Topics: Anti-Anxiety Agents; Carcinoma, Hepatocellular; Cells, Cultured; Cytochrome P-450 CYP1A1; Cytochrome | 2010 |